Company Description
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.
The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.
In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections.
Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.
The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 1998 |
| IPO Date | Nov 15, 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,600 |
| CEO | Joseph Papa |
Contact Details
Address: 400 Professional Drive, Suite 400 Gaithersburg, Maryland 20879 United States | |
| Phone | 240 631 3200 |
| Website | emergentbiosolutions.com |
Stock Details
| Ticker Symbol | EBS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001367644 |
| CUSIP Number | 29089Q105 |
| ISIN Number | US29089Q1058 |
| Employer ID | 14-1902018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph C. Papa Jr. | Chief Executive Officer, President and Director |
| Richard S. Lindahl M.B.A. | Executive Vice President, Chief Financial Officer and Treasurer |
| Coleen Glessner | Executive Vice President of Global Quality and Ethics and Compliance |
| Paul A. Williams | Senior Vice President of Products Business |
| Jessica Perl | Senior Vice President, Corporate Secretary and General Counsel |
| Michelle Pepin | Senior Vice President and Chief Human Resource Officer |
| Stephanie Duatschek | Senior Vice President, Chief Strategy and Transformation Officer |
| William Hartzel | Senior Vice President of Manufacturing and Bioservices |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 12, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 4, 2024 | 8-K | Current Report |
| Oct 2, 2024 | 8-K | Current Report |